Stock Monitor: Athersys Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free research report on Reata Pharmaceuticals, Inc. (NASDAQ: RETA). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RETA as the Company's latest news hit the wire. On March 22, 2018, the clinical-stage biopharmaceutical Company, which develops novel therapeutics for patients with serious or life-threatening diseases, reported positive top-line data from its Phase-2 LARIAT trial. The Phase-2 LARIAT trial was designed to evaluate Reata Pharma's clinical candidate bardoxolone methyl (bardoxolone) for the treatment of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Athersys, Inc. (NASDAQ: ATHX), which also belongs to the Healthcare sector as the Company Reata Pharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Reata Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Bardoxolone Methyl for Treatment of Pulmonary Hypertension
Pulmonary hypertension is a common complication of interstitial lung diseases, particularly the idiopathic pulmonary fibrosis (IPF). On an average, 50% of IPF patients develop pulmonary hypertension. Patients with pulmonary hypertension often experience chest pain, fainting episodes, shortness of breath, and swelling of ankles.
Bardoxolone methyl is an experimental, oral, once-daily activator of Nrf2 (nuclear factor-like 2). Nrf2 is a transcription factor that stimulates molecular pathways that restore the mitochondrial function and subsequently resolve inflammation. This, in turn, reduces oxidative stress, and prevents pro-inflammatory signaling.
Bardoxolone methyl has already received the orphan designation from FDA for the treatment of Alport syndrome and pulmonary arterial hypertension. At present, the drug is being evaluated in CARDINAL trial, which is a Phase-3 study for the treatment of Alport syndrome, and CATALYST trial, which is a Phase-3 study for the treatment of connective tissue disease-associated PAH (CTD-PAH).
About the Phase-2 LARIAT Trial
After Reata Pharma accomplished clinically meaningful improvements in six-minute walk distance (6MWD) in patients with CTD-PAH, it initiated small, exploratory studies in cohorts of pulmonary hypertension to explore potential expansion opportunities.
The Phase-2 LARIAT Trial aims to evaluate the effects of bardoxolone on 6MWD in patients with pulmonary hypertension and IPF or sarcoidosis, which are both common forms of interstitial lung diseases. The Phase-2 LARIAT Trial is a placebo-controlled trial, with the study duration of 16 weeks. This Trial randomized eight patients with IPF and 25 patients with sarcoidosis 2:1 to bardoxolone or placebo. This study had appropriate power to observe improvements in 6MWD compared to baseline.
So far, there are no approved therapies available for the treatment of patients with pulmonary hypertension and interstitial lung disease. The available vasodilators that are approved for pulmonary arterial hypertension have not been able to provide the requisite results in these patients.
Results demonstrated meaningful improvements in the primary endpoint while no safety signals were identified.
- Post 16 weeks of treatment, IPF patients who were administered bardoxolone showed a considerable increase in 6MWD from baseline of 38 m (p<0.05). In contrast, patients treated with placebo had a non-significant reduction of 13 m.
- Sarcoidosis patients who were administered bardoxolone also showed a noteworthy increase in 6MWD at week-16 from baseline of 17 m (p<0.05), as compared to placebo-treated patients who had a non-significant increase of 9 m.
Colin Meyer, M.D., and Chief Medical Officer at Reata Pharma shared that the extent of six-minute walk distance increases noted in IPF patients was as large as the increases observed in CTD-PAH patients in the Phase-2 LARIAT study. These initial results, especially those observed in IPF patients, are very encouraging for the Company to continue its ongoing efforts in pulmonary hypertension. Once Reata Pharma completes its other Phase-2 trials, it will amass and analyze all available data from the mid-stage trials to determine prioritization and timing for all of its programs.
Stock Performance Snapshot
March 23, 2018 - At Friday's closing bell, Reata Pharma's stock dropped 9.57%, ending the trading session at $20.69.
Volume traded for the day: 383.55 thousand shares, which was above the 3-month average volume of 196.77 thousand shares.
After last Friday's close, Reata Pharma's market cap was at $597.53 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.